Search results
Results from the WOW.Com Content Network
The most prevalent side effects include nausea, mild sedation, fatigue, and dizziness. At higher dosages, there is an increased risk for restlessness, insomnia, and tremors. [6] Cariprazine was approved for medical use in the United States in September 2015. [12] It was approved as a generic medication in 2022, [13] but is covered by patents ...
Patients who receive the drug are also counseled on this potential side effect. Users of the popular weight loss drugs have already reported a number of side effects — from personality changes ...
Note: "Notable" is to mean side-effects that are particularly unique to the antipsychotic drug in question. For example, clozapine is notorious for its ability to cause agranulocytosis. If data on the propensity of a particular drug to cause a particular AE is unavailable an estimation is substituted based on the pharmacologic profile of the drug.
Weight gain [18] There has been a study that suggests antipsychotics are associated with possible cortical reconfiguration and gray matter loss, [19] but correlational data also suggests patients who consume antipsychotics, like people with schizophrenia, tend to engage in unhealthy habits like smoking which may exacerbate gray matter loss. [20]
While most patients take GLP-1 drugs with few or no serious side effects, it's common to experience at least mild gastrointestinal issues like nausea, vomiting, stomach pain, constipation, and ...
Here are 5 of the best lean proteins to include in your diet to preserve muscle mass and stay strong while on weight-loss meds. Related: 5 Supplements You Shouldn’t Take If You’re Taking a GLP ...
It is also approved for weight loss in those that are either obese or overweight with some weight-related illnesses; Cymbalta – an antidepressant of the serotonin-norepinephrine reuptake inhibitors class
It also comes without common side effects, such as weight gain and movement disorders, found in other drugs. The lack of a warning sent Bristol Myers' shares up 6.3% at $53.28 in premarket trading ...